Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To explore the influence and the underlying mechanism of vaspin (visceral adipose tissue-derived serpin) on the development of triple-negative breast malignancy.
Methods: First, we analyzed medical records and screened out 22 breast cancer patients with different BMI according to inclusion and exclusion criterion, and measured serum vaspin of those patients. Then we studied the effects of vaspin on TNBC cell lines by using EdU assay, colony formation, transwell and wound-healing assay. Later, we used bioinformatics analysis to identify downstream effectors and verify with qRT-PCR, luciferase assay, western blot, etc. RESULTS: We found the vaspin level was positively correlated with BMI in breast malignant patients and vaspin could significantly enhance the proliferation, infiltration and transferring of triple-negative breast cancer cells by restraining the expression of miR-33a-5p. By using bioinformatic analysis and luciferase assay, we identified miR-33a-5p directly regulating ABHD2.
Conclusion: Vaspin, as a cancer-promoting cytokine, may inhibit miR-33a-5p thus increasing the level of ABHD2 to promote the development of the triple-negative breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972114 | PMC |
| http://dx.doi.org/10.1002/cam4.5241 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Berberine Sensitises Breast Cancer Cells to Radiation via the Attenuation of DNA Ligase III.
J Cell Mol Med
September 2025
College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Berberine (BBR) is an isoquinoline alkaloid with a variety of biological activities, including anti-microbial and anti-tumoral activities. However, the cellular targets of BBR and the roles of BBR in the radiosensitivity of breast cancer cells are not well defined. In this study, we investigated the effects of BBR on the radiosensitivity of BT549 triple-negative breast cancer cells.
View Article and Find Full Text PDFCyclophilin J inhibited oxidative stress and apoptosis in triple-negative breast cancer cell through activating the PI3K/Akt signaling pathway.
Toxicol Appl Pharmacol
September 2025
Department of Radiation Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China. Electronic address:
Triple-negative breast cancer (TNBC) was a highly aggressive and metastatic subtype of breast cancer characterized by a poor prognosis and limited treatment options. Clarifying the underlying molecular mechanisms was of significant clinical importance. In this study, we We plotted Kaplan-Meier survival curves based on data from the Human Cancer Database and found that elevated CYPJ expression increased patient mortality risk and decreased survival rates.
View Article and Find Full Text PDFTargeting the KRAS-p38-ATF4 axis enhances the therapeutic sensitivity of the peptide PDBAG1 in ovarian cancer via stress response modulation.
Eur J Pharmacol
September 2025
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, PR China. Electronic address:
We previously screened a peptide PDBAG1 that remarkably inhibited triple-negative breast cancer, and found that its target was C1QBP. Recently, C1QBP has been reported as a potential tumor marker in ovarian cancer, which of the mortality rate ranks first among malignant tumors of the female reproductive tract. However, it is unclear whether and how PDBAG1 plays a regulatory role in ovarian cancer.
View Article and Find Full Text PDFIn reply: SOX10 and TRPS1 in triple-negative breast cancer: Promise, pitfalls, and the need for broader validation.
Ann Diagn Pathol
September 2025
Associate Professor of Anatomic Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address:
ASO Visual Abstract: The Metaplastic Conundrum: An NCDB analysis of Metaplastic Versus Triple-Negative Ductal Breast Cancer.
Ann Surg Oncol
September 2025
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.